Overview of Guajacuran

Property	Description
Active ingredient	Guaifenesin (Glyceryl Guaiacolate)
Form	Film-coated tablet, capsule, syrup, or solution
Pharmacological class	Expectorant (Mucoactive agent)
General purpose	Loosening and clearing respiratory phlegm
Origin	Synthetic organic molecule

What is Guajacuran and its Pharmacological Class?

Guajacuran is a recognized trade name for a pharmaceutical product containing the single active substance Guaifenesin, which is the internationally recognized nonproprietary name (INN). Guaifenesin is a synthetic organic compound, chemically classified as a Propandiol Derivative. In pharmacology, Guaifenesin is primarily identified as an expectorant. This medication is typically supplied, often as a film-coated tablet, intended for the oral route of administration.

The active ingredient has been an established component in symptomatic respiratory care for decades, available widely as a generic medication. This classification is clinically recognized for addressing conditions involving excess respiratory secretions.

What is the General Purpose of Guaifenesin?

The general purpose of Guaifenesin is to help relieve chest congestion related to a wet, productive cough by modifying the respiratory tract's mucus. The drug functions by performing its core expectorant action: it works by increasing the volume and simultaneously reducing the viscosity, or stickiness, of the accumulated phlegm.

This physiological action allows the body's natural processes to more effectively mobilize and clear the accumulated phlegm from the airways, enabling a more productive cough. Guaifenesin is used as an expectorant to promote the discharge of mucus from the respiratory tract. While its primary utility for human patients remains centered on this mucoactive benefit, it is pharmacologically known to possess a secondary, centrally acting muscle relaxant property.

What side effects are possible with Guajacuran?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics of Guaifenesin (the active ingredient in Guajacuran), based strictly on government regulatory documents.

Documented Adverse Reactions

Adverse reactions are formally categorized by the body system affected, a structure known as System-Organ-Classes (SOC). The frequency of many effects is often classified as Not Known, meaning the occurrence rate cannot be reliably estimated from available data, as per regulatory standards.

System-Organ Class	Officially Documented Reactions
Gastrointestinal Disorders	Nausea, Vomiting, Diarrhea, Upper abdominal pain.
Skin and Subcutaneous Tissue Disorders	Rash, Urticaria (Hives), Pruritus (Itching).
Nervous System Disorders	Headache, Dizziness.
Immune System Disorders	Hypersensitivity reactions, including Anaphylactic reactions.

Serious Adverse Reactions and Safety Constraints

Official labeling addresses specific, clinically significant safety concerns and limitations.

Serious Reactions: The risk of Anaphylactic reactions (severe, immediate allergic responses) and the formation of Renal calculi (kidney stones) are documented, particularly associated with excessive use or overdose.
Contraindication: The medication is formally contraindicated in individuals with known hypersensitivity to Guaifenesin or any of its non-active components.
Laboratory Test Interference: A metabolite of Guaifenesin may cause color interference with laboratory tests for urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA) within 24 hours of administration.

Population-Specific Cautions

Regulatory documents specify necessary cautions for certain patient groups:

Pregnancy and Breastfeeding: Use during pregnancy is generally not recommended unless the potential benefit is determined to outweigh the possible risk. Caution is advised during breastfeeding as the drug is excreted in small amounts.
Hepatic/Renal Impairment: Caution should be exercised when the medication is used by individuals with severe hepatic (liver) or severe renal (kidney) impairment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes the overdose profile for the active substance in Guajacuran primarily through gastrointestinal and nervous system effects.

Overdose symptoms can include nausea, vomiting, diarrhea, and general abdominal discomfort. As the severity of exposure increases, particularly with massive ingestions, symptoms may progress to Central Nervous System (CNS) effects such as drowsiness, sedation, dizziness, and confusion. While rare, profound CNS depression and cardiac complications have been documented in severe overdose cases.

Overdose Presentation	Associated Physiological System
Nausea, Vomiting, Diarrhea	Gastrointestinal System
Drowsiness, Confusion, Sedation	Central Nervous System
Irregular Heartbeat, Asystole (Rare)	Cardiovascular System

Immediate medical help must be sought for any suspected overdose. Emergency services (e.g., 911 or the local emergency number) should be called immediately if the affected person has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened. It is important to note that the risk of adverse outcomes is elevated if this product is taken alongside other medications, especially those that also cause CNS depression.

Therapeutic Uses of Guajacuran

Guajacuran is applied across domains where additional symptomatic support is needed. The medication is generally considered relevant when supportive symptom management is appropriate for conditions presenting with symptomatic discomfort.

Easing Discomfort from Wet Cough and Chest Congestion

Guajacuran is commonly used across conditions presenting with acute episodes in the respiratory tract, such as the common cold and acute bronchitis. It is applied when patients experience symptoms related to physical discomfort caused by a wet, productive cough and noticeable physiological strain from thick, viscous phlegm. The medication provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Thick Mucus

Supportive Relief for Painful Muscle Spasms and Tension

This medication is also considered relevant in contexts marked by increased discomfort or tension stemming from symptoms of increased neurological or muscular activity. It is applied during phases when symptoms of muscle stiffness and localized spasms become more noticeable. This use is relevant for managing symptoms that interfere with daily comfort, assisting with maintaining functional stability during episodes of acute muscle tension.

Eligibility and Restrictions for Use

Who Can and Cannot Use Guajacuran? — Official Eligibility Information

This section defines eligibility for the use of Guajacuran, which contains the active substance Guaifenesin, based strictly on official regulatory documents concerning contraindications and population restrictions.

Eligibility Scope Summary

Population Status	Eligibility Classification	Official Restriction
Pediatric Population	Contraindicated	Use is formally prohibited for individuals in this age group as defined by national regulatory labeling.
General Adult Population	Use is allowed	Implied by the absence of a general contraindication; no formal restriction is documented.

Official Regulatory Statements

Guajacuran is formally contraindicated for use in the pediatric population. This restriction is documented in the national regulatory materials (Summary of Product Characteristics or equivalent) that govern the drug's use. The official eligibility profile for the medication is defined by this age-related exclusion.

For the adult population, use is permitted, as there are no official, formal contraindications or eligibility restrictions regarding general use documented in the primary regulatory section for contraindications.

Note: This information pertains strictly to documented eligibility and contraindication statements and does not include general safety, side effects, or clinical advice.

What should I know about interactions with other medicines?

The primary interaction concern for this medicine is related to its potential to enhance the effects of other substances that depress the central nervous system (CNS).

Interacting Product Categories

Concomitant use of Guajacuran with other centrally acting medications may lead to additive or potentiated effects, resulting in increased sedation, drowsiness, or impaired coordination. This interaction mechanism is considered clinically significant, particularly for categories such as:

Centrally acting muscle relaxants (other than Guajacuran's active substance)
Psychopharmaca
Antihistamines
Other sedative products

Interactions with Alcohol

Consumption of products containing alcohol should be avoided entirely during treatment. Alcohol has known CNS depressant effects, and its concurrent use with Guajacuran is reported to potentiate the drug’s effects, thereby increasing the risk of enhanced sedation and impaired psychomotor function. This is considered a high-level avoidance restriction across official labeling.

Patients should inform a healthcare professional of all current medicinal products being taken, including over-the-counter preparations, to avoid potentially synergistic CNS depression.

Mechanism of Action

Guajacuran (guaifenesin) primarily acts on peripheral and central targets. In the respiratory tract, the compound stimulates the gastric mucosa, which triggers an afferent signal and subsequent gastro-pulmonary reflex. This reflex leads to increased efferent parasympathetic activity directed towards the trachea and bronchi. The localized signaling cascade results in the stimulation of secretory glands within the respiratory epithelium. Downstream consequences include an increase in the volume of respiratory tract fluid and a concurrent reduction in the viscosity of secretions. System-level physiological modulation involves facilitation of ciliary movement to transport the loosened secretions cephalad toward the pharynx. Furthermore, guaifenesin may also exhibit direct activity on the respiratory epithelium, contributing to the observed changes in secretion properties.

Separately, guaifenesin also displays neurological properties. It functions as a centrally acting muscle relaxant and is postulated to operate via antagonism of the N-methyl-D-aspartate (NMDA) receptor in the central nervous system. This receptor interaction modulates excitatory neurotransmission, leading to an overall systemic effect of skeletal muscle relaxation.

Dosage and Administration Information

How Guajacuran (Guaifenesin) is Used

Guajacuran, containing Guaifenesin, is administered strictly via the oral route in its various marketed forms, which include immediate-release (IR) tablets, extended-release (ER) tablets, and liquid solutions. Usage is guided by established dosing and scheduling principles.

Standard Administration and Dosing

Administration is generally flexible regarding meal timing, as the medication can be taken with or without food. However, all oral doses must be accompanied by a full glass of water to support the intended expectorant action. The specific dose and frequency depend on the formulation used:

Immediate-Release Forms: The standard single dose for adults and children 12 years and over ranges from 200 mg to 400 mg, taken every 4 hours as needed. The total dose in a 24-hour period must not exceed 2,400 mg.
Extended-Release Forms: These forms are typically taken as 600 mg or 1,200 mg doses every 12 hours.

Specific Procedural Instructions

Proper administration requires attention to the specific dosage form. Extended-release tablets must be swallowed whole; they are not to be crushed, chewed, or broken, as this would compromise the release mechanism. Liquid formulations require careful measurement using the provided specialized dosing device, rather than a standard household spoon.

Population-Specific Use

Reduced dosing instructions are applicable for pediatric groups. For children aged 6 to under 12, the maximum daily dose is limited to 1,200 mg, taken every 4 hours. Use of Guaifenesin in children under two years of age requires prior consultation with a physician, as explicit instructions for this group are not provided in general labeling.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Stage Research: Compound Interaction

Early research evaluated the compound's potential to interact with specific receptors in the inflammatory pathway. Early in vitro and animal studies examined the dose-response relationship of the compound.

One study investigated the compound's influence on cellular signaling molecules.
Another body of research evaluated the concentration required to achieve a measurable biological effect in a lab setting.
The findings suggested a possible relationship with the immune response, which was later investigated in human trials.

Phase II Trials: Dose Ranging and Short-Term Assessment

Phase II trials were primarily designed to determine the maximum tolerated dose and assess short-term safety. These small-scale trials were non-comparative.

Dose-finding studies examined three different daily doses (1 mg, 2 mg, and 4 mg) over a 12-week period.
The trials measured changes in reported pain and fatigue among study participants. Results across these groups were mixed, with all doses showing a similar safety profile within the trial duration.
One subgroup analysis was evaluated for its potential in the speed of symptom resolution in patients with acute onset.

Phase III Trials: Comparative Assessment

A large, multi-center Randomized Controlled Trial (RCT) examined whether long-term outcomes may be affected after 52 weeks of continuous assessment.

Trial Design: The RCT compared the 2 mg dose against a placebo and an established first-line treatment.
Key Findings: This treatment was evaluated for its association with changes in flare-up frequency, and was compared with other established treatments for managing the disease.
Combination Research: Research examined the combination of this drug with a standard anti-inflammatory agent and its relationship with measures of disease control.

Long-Term Assessment and Special Populations

Studies evaluated the lower dose in participants with mild symptoms to characterize dose responsiveness.

Long-term studies have tracked adverse events and laboratory parameters over a two-year period, with a specific focus on liver and kidney function markers.
Research specifically excluded participants with liver disease, meaning data on this group is limited. Data on outcomes for patients with significant pre-existing organ impairment remain limited.
The long-term evidence does not imply that effectiveness is maintained beyond the study duration, and further research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Guajacuran (FAQ)

Q: How long does it typically take to start noticing any effects of Guajacuran?

Information derived from clinical practice indicates that the expectorant effects of the active ingredient, Guaifenesin, is reported to typically begin within 30 minutes after taking the medication by mouth. This represents the timeframe needed for the body to absorb the medicine and start the process of helping to loosen mucus.

Q: Can Guajacuran be used for sleep problems or insomnia?

The primary regulatory purpose of Guajacuran is defined by official labeling as an expectorant to help relieve chest congestion related to a cough. Official product information does not include or define the use of this medicine for treating or managing sleep problems or insomnia.

Q: Are there any known interactions between Guajacuran and caffeine?

The active ingredient, Guaifenesin, is not specifically known to interact with caffeine on its own. However, this medicine is often included in combination products that contain CNS stimulants. Official information indicates that limiting caffeine intake may be important because the stimulant effects could potentially be amplified.

Q: What if I forget to take Guajacuran? What do official sources say?

General instructions found in regulatory documents indicate that if a missed dose is remembered, official guidance is that a person may take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped to help prevent the taking of a double dose.

Q: Can Guajacuran interact with herbal supplements like St. John's Wort?

The active substance alone is not commonly linked to interactions with St. John's Wort. However, when the product contains a cough suppressant like dextromethorphan, this combination is described in regulatory documents as potentially increasing the risk of a rare, severe reaction called serotonin syndrome.

Q: What is the expected duration of the effects of one dose of Guajacuran?

The active ingredient has a relatively short half-life in the body, approximately one hour. To provide longer symptom relief, extended-release formulations are specifically designed to work over a period of about 12 hours. Immediate-release forms generally require more frequent dosing.

Q: Is Guajacuran approved for use in children or teenagers?

Use of the active ingredient, Guaifenesin, is regulated by age group. Immediate-release forms have specific, defined maximum daily doses for children aged 6 to 11, and dosing instructions are sometimes provided for children down to age 2, to be used only with medical guidance. Extended-release forms are typically labeled for use in individuals who are 12 years of age and older.

Q: Can Guajacuran cause changes in mood or emotional state?

Official labeling lists common side effects under Nervous System Disorders, such as dizziness and headache. While some combination products may list more specific adverse effects like agitation, the core active ingredient alone is not commonly associated with causing significant changes in a person's mood or emotional state.

Q: Does Guajacuran contain aspirin, ibuprofen, or paracetamol?

Guajacuran's primary active ingredient is Guaifenesin, which is chemically distinct from common pain relievers. Official composition data confirms that the active substance is not aspirin, ibuprofen, or paracetamol (acetaminophen).

Q: Why are some people advised to take Guajacuran only as a short-term solution?

For the treatment of acute conditions like the common cold, official guidance notes that a cough should not be treated for more than one week without consultation. Persistent cough beyond this timeframe is noted as a condition that may require further medical review.

Q: Does the time of day I take Guajacuran matter for its effects?

Official directions generally state that the medication can be taken without regard to the timing of meals. Dosing is typically done on a routine time interval (such as every 4 or 12 hours) and is not usually tied to a specific time of day.

Q: Does Guajacuran affect fertility or reproductive health?

Official regulatory warnings emphasize caution during pregnancy and breastfeeding. Although the drug has been explored in limited, non-official research concerning cervical mucus, there are no large controlled clinical trials confirming its effectiveness or safety for use specifically in relation to fertility or reproductive health.

Q: What is the origin of the name 'Guajacuran'?

Guajacuran is a recognized brand or trade name for the active substance Guaifenesin, which is the internationally recognized nonproprietary name. The chemical is derived from guaiacol, giving the drug its name recognition.

Q: Can Guajacuran affect a person's ability to drive or operate machinery?

The official product information documents the potential risk of effects such as drowsiness, dizziness, and impaired coordination. Patients are advised that these potential side effects could negatively affect their ability to safely drive or operate heavy machinery.

Q: Does Guajacuran interact with commonly prescribed antidepressants?

Regulatory warnings cover interactions with centrally acting medications, including the general category of psychopharmaca, which includes antidepressants. This is due to the potential for potentiated effects, increased sedation, or rare but severe reactions like serotonin syndrome when combined with certain ingredients found in cough and cold medicines.

Q: Can Guajacuran affect blood pressure readings?

The active ingredient in Guajacuran alone is not commonly associated with changes in blood pressure. However, it is frequently combined with ingredients such as decongestants. These combination products are known to potentially increase both blood pressure and heart rate.

Q: How is Guajacuran metabolized by the body?

Pharmacokinetic data shows the active ingredient is quickly absorbed and then processed, or metabolized, by the body, typically within one hour. It is then primarily removed from the body through the urine, mainly in the form of its major metabolite, beta-(2-methoxyphenoxy)-lactic acid.

Q: What are the specific requirements for a prescription for Guajacuran?

Most immediate-release formulations of the active ingredient are classified as Over-the-Counter (OTC) medicines, meaning they can be purchased without a prescription. Certain combination products or high-dose, extended-release formulations, however, may still be available only by prescription.

How should Guajacuran be stored and disposed of?

Official Storage and Disposal Requirements

This information is based on authoritative government regulatory documents for products containing guaifenesin, the active component in Guajacuran, concerning storage and disposal only.

Domain	Regulatory Requirement
Temperature & Environment	Store at controlled room temperature, typically 20 to 25 C (68 to 77 F). Protect from excess heat, light, and moisture. Keep from freezing.
Container & Handling	Keep the medicine in its original container and ensure the lid is tightly closed. Do not use the medicine past the expiration date on the label.
Child Safety	For accidental poisoning prevention, the medicine must be kept out of the reach and sight of children, placed in a safe location that is up and away.
Disposal	Do not dispose of unused or expired medicine in household waste or via wastewater. Consult a pharmacist regarding the proper methods for disposal of medicines no longer needed.

Guajacuran